MYC and acute myeloid leukemia: To investigate whether WBC100 selectively kills c‐Myc overexpressing cancer cells, we treated c‐Myc overexpressing human cancer cell lines Mia‐paca2 (PDAC), H9 (T‐cell lymphoma), and MOLM‐13 (acute myeloid leukemia) as well as c‐Myc‐low normal human cell lines L02 (liver), MRC‐5 (lung) and WI38 (lung) with WBC100 at various concentrations for 72 h.